AUTL
NASDAQAutolus Therapeutics plc
Price$1.45+0.02 (+1.40%)
01:30 PM07:45 PM
News · 26 weeks67+300%
2026-01-182026-07-12
Mix2890d
- Other10(36%)
- Insider9(32%)
- SEC Filings7(25%)
- Earnings2(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Young William D4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Rao Madduri Ravin4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Richardson Ryan4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Leiderman Elisabeth4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Iannone Robert4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Butitta Cynthia M4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Bain Linda4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Azelby Robert4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Bonney Michael W4 - Autolus Therapeutics plc (0001730463) (Issuer)
- PRAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 13 employees pursuant to the Company’s 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autolus
- SECAutolus Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics to Participate in Upcoming Investor ConferenceLONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, June 30, 2026 at 9:00am EDT / 14:00pm BST. A webcast of the fireside chat will be available on the "Events" page in the "Investor Relations & Media" section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of
- PRAutolus Therapeutics Receives Prix Galien UK AwardLONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare. "We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pio
- SECAutolus Therapeutics plc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics to Participate in Upcoming Investor ConferencesLONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences. William Blair's 46th Annual Growth Stock ConferenceDate and time: June 2, 2026; 1:20pm CDT / 7:20pm BSTLocation: Chicago, ILPresenter: Chief Executive Officer Dr. Christian Itin Jefferies Global Healthcare ConferenceDate and time: June 3, 2026; 10:30am EDT / 3:30pm BSTLocation: New York, NYPresenter: Chief Executive Officer Dr. Christian Itin Webcasts of the pres
- PRAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. "Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plcSCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plcSCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
- SECSEC Form 10-Q filed by Autolus Therapeutics plc10-Q - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesAUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underwayObe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LON
- SECSEC Form EFFECT filed by Autolus Therapeutics plcEFFECT - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form EFFECT filed by Autolus Therapeutics plcEFFECT - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required
- SECAutolus Therapeutics plc filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure8-K - Autolus Therapeutics plc (0001730463) (Filer)
AUTL FAQ
7 questionsWhat does Autolus Therapeutics plc do?
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is...Where does AUTL stock trade?
Autolus Therapeutics plc (AUTL) is listed on NASDAQ.What sector and industry is AUTL in?
Autolus Therapeutics plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Autolus Therapeutics plc go public?
Autolus Therapeutics plc (AUTL) completed its IPO in 2018.What are analysts saying about AUTL?
Autolus Therapeutics plc has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-02-17. Recent price targets range from $500.00 to $1300.00.What companies are similar to AUTL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AUTL side-by-side with any of them on Quantisnow.How can I track AUTL on Quantisnow?
Quantisnow aggregates Autolus Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AUTL to receive live email and push alerts on every new disclosure.